Our Mission

Our Mission

Our Mission


Overcoming Limitations of Current Treatment Paradigms

Despite recent advancements, the current cancer treatment paradigm has failed to achieve deep and durable responses in most cancers due to the development of treatment resistance, relapse and metastasis.

Our research suggests that activation of adaptive stress pathways modulates such tumor escape mechanisms by reprogramming the phenotype of cancer cells to enable their survival in the harsh tumor microenvironment, allowing them to achieve resistance and metastasis.

Our clinical-stage therapeutic candidates are designed to modulate these critical pathways and represent a novel approach for addressing treatment resistance, cancer relapse and metastasis.

A Differentiated Approach to Improving Cancer Therapy

We are a clinical-stage oncology company focused on discovering and developing novel therapeutic candidates to provide patients with treatment options that help them live longer, cancer-free lives. HiberCell was launched in 2019 with investor support from ARCH Venture Partners and other leading life science investors.

Clinical Development and Discovery

Clinical Development and Discovery

Clinical Development and Discovery

We have industry-leading tools for the analysis of complex data sets that enable novel phenotypic insights and clinical-genomic observations that we believe will help identify patients who are most likely to respond to our therapies. We believe that combining our insights into adaptive stress pathways with our proprietary QuAD³ platform will advance our understanding of cancer, as well as other disease areas. Our QuAD3 platform is further designed to enable patient-centric, informed drug discovery and development, and we plan to use our QuAD3 Platform to enhance the development of our existing and future therapy candidates.